In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Impaired circadian properties of Beat to Beat Deceleration Capacity of heart rate predict arrhythmic events in heart failure patients.

Session Poster session 6

Speaker Polychronis E Dilaveris

Congress : ESC Congress 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Arrhythmias, General - Diagnostic Methods
  • Session type : Poster Session
  • FP Number : P5521

Authors : P Arsenos (Athens,GR), G Manis (Ioannina,GR), KA Gatzoulis (Athens,GR), P Dilaveris (Athens,GR), S Sideris (Athens,GR), E Sotiropoulos (Athens,GR), A Trikas (Athens,GR), C Stefanadis (Athens,GR), D Tousoulis (Athens,GR)


P. Arsenos1 , G. Manis2 , K.A. Gatzoulis1 , P. Dilaveris1 , S. Sideris3 , E. Sotiropoulos3 , A. Trikas4 , C. Stefanadis1 , D. Tousoulis1 , 1University of Athens, Hippokration Hospital, First Cardiology Division - Athens - Greece , 2University of Ioannina, Department of Computer Science and Engineering - Ioannina - Greece , 3Hippokration Hospital, State Cardiology Department - Athens - Greece , 4Elpis General Hospital, Cardiology Department - Athens - Greece ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 1181

Background: Conventional Deceleration Capacity (DC) method is an established total mortality predictor in post-myocardial infarction patients. We introduced a new DC variant based on a Beat to Beat DC (BBDC) calculation algorithm.

Purpose: The circadian properties of the BBDC were investigated and assessed for possible risk stratification application.

Methods: Twenty four hour Holter ECG signals from 220 Heart failure patients (age=65±13 years, male=84%, LVEF=32±10%) were analysed for: Entire 24 hours (08.00–08.00), Day (06.00–23.00), Night (23.00–06.00). BBDC were calculated for each period. The difference between night (BBDCnight) and day (BBDCday) accepted as the Circadian BBDC (Circ. BBDC). After 41 months, 57 patients had Sudden Cardiac Death (SCD) end-points.

Results: From univariate analysis for SCD+ and SCD- groups: BBDC24h: 6.4±1.7ms vs 7.0±2.0ms, (p=0.03). BBDCday:6.2±1.7ms vs 6.7±1.9ms, (p=0.1). BBDCnight:6.6±1.9 ms vs 7.5±2.3 ms (p=0.03). Circ. BBDC: 0.3±1.4ms vs 0.7±1.2ms, (p=0.03). After Cox regression analysis adjusted for Circ.BBDC, Gender, QRS duration, QTc interval (Fridericia), Circ.BBDC was an independent SCD predictor (HR: 0.768, 95% CI: 0.601–0.981, p=0.03). Circ BBDC values distribution across the percentiles were: 1st: -2ms, 25th: -0.2ms, 50th: 0.6ms, 75th: 1.4ms, 90th: 2.5 ms, 99th: 4.2 ms. The cut off point of -0.2 ms (25th percentile) in the same Cox regression model presented HR: 1.843 for SCD (95% CI: 1.031–3.293, p=0.03).

Conclusions: BBDC Circardian properties are impaired in patients prone to SCD. Patients with absence of circadian adaptation and Circ BBDC values less than -0.2 ms, present Hazard Ratio 1.843 for SCD. Further clinical investigation is needed.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are